Skip to main content

Table 2 Anti-proliferative activity of tested compounds on PC-3 and HDF cells during 24, 48, and 72 h of treatments

From: Investigating the effects of two novel 4-MMPB analogs as potent lipoxygenase inhibitors for prostate cancer treatment

Compounds IC50 (µM) ± SD (PC-3) IC50 (µM) ± SD (HDF)
24 h 48 h 72 h 24 h 48 h 72 h
4-PMPB 122.303 ± 2.618 88.45 ± 2.312 57.58 ± 2.123 1641.10 ± 0.075 1443.73 ± 0.055 1028.86 ± 0.139
4-EMPB 107.44 ± 6.17 74.95 ± 3.39 48.99 ± 6.76 545.55 ± 1.99 361.70 ± 2.29 258.87 ± 1.86
4-MMPB 100.76 ± 2.412 55.55 ± 1.980 40.79 ± 1.795 331.42 ± 3.332 284.09 ± 2.975 185.61 ± 2.805
Cisplatin 62.29 ± 1.741 51.53 ± 1.425 41.63 ± 1.108 153.42 ± 2.89 119.49 ± 2.565 71.09 ± 3.337